drugset / Trial / NCT02516618

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

NCT02516618

Phase 1 Completed 72 enrolled Regeneron Pharmaceuticals
RandomizedSingle-groupQuadruple-blindBasic science

Summary

The primary objective of the study is to assess the safety and tolerability of a single dose of subcutaneous (SC) or intravenous (IV) administered fasinumab in healthy Japanese subjects.

Timeline

Start
2015-07
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fasinumab Monoclonal antibody Subcutaneous

Indications

No indication recorded.